Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Bray
Mark Buller

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
Antiviral Research|October 2, 2007
Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox modelScott Parker, Erin Touchette, Christina Oberle, et al.
Antiviral Research|November 25, 2006
Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in miceKarl Y Hostetler, James R Beadle, Julissa Trahan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2008
Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complexNassima Fodil-Cornu, Seung-Hwan Lee, Simon Belanger, et al.
Antiviral Research|September 16, 2021
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challengeScott Parker, June D'Angelo, R Mark Buller, et al.
Antiviral Research|August 5, 2017
Highlights of the 30th International Conference on Antiviral ResearchGraciela Andrei, Kara Carter, Zlatko Janeba, et al.
Vaccine|November 9, 2010
VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response aloneLeonard Moise, R Mark Buller, Jill Schriewer, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Estimating Sedentary Breathing Rate from Chest-Worn Accelerometry From Free-Living DataBrian A Telfer, James R Williamson, Lara Weed, et al.
Journal of Virology|August 19, 2011
The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responsesCarolina R Melo-Silva, David C Tscharke, Mario Lobigs, et al.
Plos Pathogens|June 25, 2015
Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or ActivationJanet J Sei, Scott Haskett, Lauren W Kaminsky, et al.
Bioorganic & Medicinal Chemistry|April 16, 2011
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenineJacqueline Ruiz, James R Beadle, R Mark Buller, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
Antiviral Research|October 2, 2007
Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox modelScott Parker, Erin Touchette, Christina Oberle, et al.
Antiviral Research|November 25, 2006
Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in miceKarl Y Hostetler, James R Beadle, Julissa Trahan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2008
Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complexNassima Fodil-Cornu, Seung-Hwan Lee, Simon Belanger, et al.
Antiviral Research|September 16, 2021
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challengeScott Parker, June D'Angelo, R Mark Buller, et al.
Antiviral Research|August 5, 2017
Highlights of the 30th International Conference on Antiviral ResearchGraciela Andrei, Kara Carter, Zlatko Janeba, et al.
Vaccine|November 9, 2010
VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response aloneLeonard Moise, R Mark Buller, Jill Schriewer, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Estimating Sedentary Breathing Rate from Chest-Worn Accelerometry From Free-Living DataBrian A Telfer, James R Williamson, Lara Weed, et al.
Journal of Virology|August 19, 2011
The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responsesCarolina R Melo-Silva, David C Tscharke, Mario Lobigs, et al.
Plos Pathogens|June 25, 2015
Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or ActivationJanet J Sei, Scott Haskett, Lauren W Kaminsky, et al.
Bioorganic & Medicinal Chemistry|April 16, 2011
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenineJacqueline Ruiz, James R Beadle, R Mark Buller, et al.
Pageof 14